Gabor M. Rubanyi

Former Adjunct Professor-Molecular & Cellular Physiology at University of California - Davis

Gabor M. Rubanyi

Gabor M. Rubanyi

Former Adjunct Professor-Molecular & Cellular Physiology at University of California - Davis

Overview
Career Highlights

NanoCor Therapeutics, Inc.

RelSci Relationships

2056

Number of Boards

4

Birthday

1947

Age

72

Contact Data
Trying to get in touch with Gabor M. Rubanyi? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Gabor M. Rubanyi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Vice Chairman, President & Chief Executive Officer at Schering Berlin, Inc.

Relationship likelihood: Strong

Global Project Leader, Ophthalmology Programs at Auven Therapeutics Management LLLP

Relationship likelihood: Strong

President & Chief Executive Officer at Nektar Therapeutics

Relationship likelihood: Strong

Co-Founder at X4 Pharmaceuticals, Inc.

Relationship likelihood: Strong

Vice President-Vector Biology at BioMarin Pharmaceutical, Inc.

Relationship likelihood: Strong

David Wesley Gaiser Professor of Biological Chemistry, Department of Biological Chemistry & Molecular Pharmacology at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Founder at Unity Biotechnology, Inc.

Relationship likelihood: Strong

Vice Dean at UCSF School of Medicine

Relationship likelihood: Strong

Executive Chairman at Titan Pharmaceuticals Inc.

Relationship likelihood: Strong

Former President at Grifols Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Gabor M. Rubanyi
Potential Connections via
Relationship Science
You
Gabor M. Rubanyi
Former Adjunct Professor-Molecular & Cellular Physiology at University of California - Davis
Career History
Adjunct Professor-Molecular & Cellular Physiology
Tenure Unconfirmed

The University of California, Davis (also referred to as UCD, UC Davis, or Davis) is a public teaching and research university located in Davis, California just west of Sacramento. The campus covers 7,309 acres (2,958 ha), making it the largest within the 10 campus University of California system. UC Davis also has the third largest enrollment in the UC System after UCLA and UC Berkeley. The University of California, Davis campus is the largest campus in the UC system by land area, spanning 7,309 acres (2,957.8 ha) across two counties: Yolo and Solano. Though named after the City of Davis, the campus is technically located adjacent to the City of Davis in an unincorporated part of Yolo and Solano counties. The main campus is located 15 miles (24.1 km) west of Sacramento in the Sacramento Valley, part of California's Central Valley, and is adjacent to Interstate Highway 80. The Davis campus is the only school within the UC system with an airport, just west of main campus, and is one of two UC schools with its own fire department; the other being UC Santa Cruz. The campus is also conveniently located approximately an hour away from both San Francisco and the Napa Valley and two hours from Lake Tahoe. It is also one of only three schools in the University of California system, the others being UC Berkeley and UC Irvine, with a nuclear lab.

Scientific Advisor
2006 - Prior

Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company . The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.

Co-Founder
2005 - Prior

NanoCor Therapeutics, Inc. provides biotechnology products and services. It focuses on treating cardiovascular disease at the molecular level. The company was founded by Roger A. Hajjar, Sheila A. Mikhail, and Gabor M. Rubanyi in 2005 and is headquartered in Chapel Hill, NC.

Boards & Committees
Member, Scientific Advisory Board
Current

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Sangamo was founded in 1995, went public in 2000, and trades on the Nasdaq Global Market (SGMO). We are located in Richmond, California, in the Bay Area, the birthplace of biotechnology. We are intimately involved in our community through partnerships with academic institutions, relationships with non-profit organizations and ties to advocacy organizations aligned with improving the quality of life for patients with unmet medical needs within our strategic vision.

Director
2006 - Prior

Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services.Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding.With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification.Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage.

Member, Board of Directors
Prior
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Gabor M. Rubanyi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Gabor M. Rubanyi's profile does not indicate a business or promotional relationship of any kind between RelSci and Gabor M. Rubanyi.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/gabor-m-rubanyi-3490967
  • https://relationshipscience.com/person/gabor-m-rubanyi-3490967